Novel and emerging drugs for chronic lymphocytic leukemia

Current Cancer Drug Targets

Volumn 12, Issue 5, 2012, Pages 471-483

  Isfort, S ^a   Cramer, P ^a   Hallek, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

B cell receptor inhibitors; Chronic lymphocytic leukemia; Monoclonal antibodies; Novel drugs; Treatment; Tyrosine kinase inhibitors

Indexed keywords

5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BENDAMUSTINE; BI 836826; BLINATUMOMAB; CHIR 12.12; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACETUZUMAB; DASATINIB; DEXAMETHASONE; DINACICLIB; EVEROLIMUS; FLAVOPIRIDOL; FLUDARABINE; FOSTAMATINIB; IBRUTINIB; ISF 35; ISOSORBIDE; LENALIDOMIDE; LUCATUMUMAB; LUMILIXIMAB; MAPATUMUMAB; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NAVITOCLAX; OBATOCLAX; OBINUTUZUMAB; OBLIMERSEN; OFATUMUMAB; P 505 15; PRT 318; RITUXIMAB; TRU 016; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMYLASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; APRAXIA; ATAXIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CONJUNCTIVITIS; CONTINUOUS INFUSION; DIARRHEA; DISORIENTATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; EUPHORIA; FEVER; HEADACHE; HODGKIN DISEASE; HUMAN; ILEUS; INFECTION; INFUSION RELATED REACTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PNEUMONIA; REVIEW; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; SPEECH DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR LYSIS SYNDROME; VISUAL DISORDER;

EID: 84861750360     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912800673257     Document Type: Review

References (79)

1. Bottcher, S.; Ritgen, M.; Fischer, K.; Stilgenbauer, S.; Busch, R. M.; Fingerle-Rowson, G.; Fink, A. M.; Buhler, A.; Zenz, T.; Wenger, M. K.; Mendila, M.; Wendtner, C. M.; Eichhorst, B. F.; Dohner, H.; Hallek, M. J.; Kneba, M. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J. Clin. Oncol. 2012, 30 (9), 980-988.
2. Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A. M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; von Grunhagen, U.; Bergmann, M.; Catalano, J.; Zinzani, P. L.; Caligaris-Cappio, F.; Seymour, J. F.; Berrebi, A.; Jager, U.; Cazin, B.; Trneny, M.; Westermann, A.; Wendtner, C. M.; Eichhorst, B. F.; Staib, P.; Buhler, A.; Winkler, D.; Zenz, T.; Bottcher, S.; Ritgen, M.; Mendila, M.; Kneba, M.; Dohner, H.; Stilgenbauer, S. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376 (9747), 1164-1174.
3. Dreger, P.; Dohner, H.; Ritgen, M.; Bottcher, S.; Busch, R.; Dietrich, S.; Bunjes, D.; Cohen, S.; Schubert, J.; Hegenbart, U.; Beelen, D.; Zeis, M.; Stadler, M.; Hasenkamp, J.; Uharek, L.; Scheid, C.; Humpe, A.; Zenz, T.; Winkler, D.; Hallek, M.; Kneba, M.; Schmitz, N.; Stilgenbauer, S. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010, 116 (14), 2438-2447.
4. Cragg, M. S.; Walshe, C. A.; Ivanov, A. O.; Glennie, M. J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 2005, 8, 140-174
5. Teeling, J. L.; Mackus, W. J.; Wiegman, L. J.; van den Brakel, J. H.; Beers, S. A.; French, R. R.; van Meerten, T.; Ebeling, S.; Vink, T.; Slootstra, J. W.; Parren, P. W.; Glennie, M. J.; van de Winkel, J. G. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006, 177 (1), 362-371.
6. Wierda, W. G.; Kipps, T. J.; Mayer, J.; Stilgenbauer, S.; Williams, C. D.; Hellmann, A.; Robak, T.; Furman, R. R.; Hillmen, P.; Trneny, M.; Dyer, M. J.; Padmanabhan, S.; Piotrowska, M.; Kozak, T.; Chan, G.; Davis, R.; Losic, N.; Wilms, J.; Russell, C. A.; Osterborg, A. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2010, 28 (10), 1749-1755.
7. Wierda, W. G.; Kipps, T. J.; Durig, J.; Griskevicius, L.; Stilgenbauer, S.; Mayer, J.; Smolej, L.; Hess, G.; Griniute, R.; Hernandez-Ilizaliturri, F. J.; Padmanabhan, S.; Gorczyca, M.; Chang, C. N.; Chan, G.; Gupta, I.; Nielsen, T. G.; Russell, C. A. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011, 117 (24), 6450-6458.
8. Patz, M.; Isaeva, P.; Forcob, N.; Muller, B.; Frenzel, L. P.; Wendtner, C. M.; Klein, C.; Umana, P.; Hallek, M.; Krause, G. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br. J. Haematol. 2011, 152 (3), 295-306.
9. Mössner, E.; Brunker, P.; Moser, S.; Puntener, U.; Schmidt, C.; Herter, S.; Grau, R.; Gerdes, C.; Nopora, A.; van Puijenbroek, E.; Ferrara, C.; Sondermann, P.; Jager, C.; Strein, P.; Fertig, G.; Friess, T.; Schull, C.; Bauer, S.; Dal Porto, J.; Del Nagro, C.; Dabbagh, K.; Dyer, M. J.; Poppema, S.; Klein, C.; Umana, P. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115 (22), 4393-4402.
10. Kijimoto-Ochiai, S. CD23 (the low-affinity IgE receptor) as a Ctype lectin: a multidomain and multifunctional molecule. Cell. Mol. Life Sci. 2002, 59 (4), 648-664.
11. Byrd, J. C.; O'Brien, S.; Flinn, I. W.; Kipps, T. J.; Weiss, M.; Rai, K.; Lin, T. S.; Woodworth, J.; Wynne, D.; Reid, J.; Molina, A.; Leigh, B.; Harris, S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res. 2007, 13 (15 Pt 1), 4448-4455.
12. Byrd, J. C.; Kipps, T. J.; Flinn, I. W.; Castro, J.; Lin, T. S.; Wierda, W.; Heerema, N.; Woodworth, J.; Hughes, S.; Tangri, S.; Harris, S.; Wynne, D.; Molina, A.; Leigh, B.; O'Brien, S. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010, 115 (3), 489-495.
13. Virtaneva, K. I.; Angelisova, P.; Baumruker, T.; Horejsi, V.; Nevanlinna, H.; Schroder, J. The genes for CD37, CD53, and R2, all members of a novel gene family, are located on different chromosomes. Immunogenetics 1993, 37 (6), 461-465.
14. Nagorsen, D.; Bargou, R.; Ruttinger, D.; Kufer, P.; Baeuerle, P. A.; Zugmaier, G. Immunotherapy of lymphoma and leukemia with Tcell engaging BiTE antibody blinatumomab. Leuk. Lymphoma. 2009, 50 (6), 886-891.
15. Bargou, R.; Leo, E.; Zugmaier, G.; Klinger, M.; Goebeler, M.; Knop, S.; Noppeney, R.; Viardot, A.; Hess, G.; Schuler, M.; Einsele, H.; Brandl, C.; Wolf, A.; Kirchinger, P.; Klappers, P.; Schmidt, M.; Riethmuller, G.; Reinhardt, C.; Baeuerle, P. A.; Kufer, P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321 (5891), 974-977.
16. Advani, R.; Forero-Torres, A.; Furman, R. R.; Rosenblatt, J. D.; Younes, A.; Ren, H.; Harrop, K.; Whiting, N.; Drachman, J. G. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 2009, 27 (26), 4371-4377.
17. Furman, R. R.; Forero-Torres, A.; Shustov, A.; Drachman, J. G. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 2010, 51 (2), 228-235.
18. Lewis, T. S.; McCormick, R. S.; Emmerton, K.; Lau, J. T.; Yu, S. F.; McEarchern, J. A.; Grewal, I. S.; Law, C. L. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin. Cancer Res. 2011, 17 (14), 4672-4681
19. Lapalombella, R.; Gowda, A.; Joshi, T.; Mehter, N.; Cheney, C.; Lehman, A.; Chen, C. S.; Johnson, A. J.; Caligiuri, M. A.; Tridandapani, S.; Muthusamy, N.; Byrd, J. C. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br. J. Haematol. 2009, 144 (6), 848-855.
20. Luqman, M.; Klabunde, S.; Lin, K.; Georgakis, G. V.; Cherukuri, A.; Holash, J.; Goldbeck, C.; Xu, X.; Kadel, E. E., 3rd; Lee, S. H.; Aukerman, S. L.; Jallal, B.; Aziz, N.; Weng, W. K.; Wierda, W.; O'Brien, S.; Younes, A. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008, 112 (3), 711-720.
21. Byrd, J. C.; Kipps, T. J.; Flinn, I. W.; Cooper, M.; Odenike, O.; Bendiske, J.; Rediske, J.; Bilic, S.; Dey, J.; Baeck, J.; O'Brien, S. Phase 1 Study of the anti-CD40 Humanized Monoclonal antibody lucatumumab (HCD122) in Relapsed Chronic Lymphocytic Leukemia. Leuk. Lymphoma 2012, [Epub ahead of print].
22. Wierda, W. G.; Castro, J. E.; Aguillon, R.; Sampath, D.; Jalayer, A.; McMannis, J.; Prussak, C. E.; Keating, M.; Kipps, T. J. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 2010, 24 (11), 1893-1900.
23. Melo-Cardenas, J.; Urquiza, M.; Kipps, T. J.; Castro, J. E. Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression. Cancer Gene Ther. 2012, 19 (5), 336-344.
24. Moretto, P.; Hotte, S. J. Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1. Expert. Opin. Investig. Drugs 2009, 18 (3), 311-325.
25. Frenzel, L. P.; Patz, M.; Pallasch, C. P.; Brinker, R.; Claasen, J.; Schulz, A.; Hallek, M.; Kashkar, H.; Wendtner, C. M. Novel Xlinked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br. J. Haematol. 2011, 152 (2), 191-200.
26. Younes, A.; Vose, J. M.; Zelenetz, A. D.; Smith, M. R.; Burris, H. A.; Ansell, S. M.; Klein, J.; Halpern, W.; Miceli, R.; Kumm, E.; Fox, N. L.; Czuczman, M. S. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br. J. Cancer 2010, 103 (12), 1783-1787.
27. Petlickovski, A.; Laurenti, L.; Li, X.; Marietti, S.; Chiusolo, P.; Sica, S.; Leone, G.; Efremov, D. G. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005, 105 (12), 4820-4827.
28. Dal-Bo, M.; Del Giudice, I.; Bomben, R.; Capello, D.; Bertoni, F.; Forconi, F.; Laurenti, L.; Rossi, D.; Zucchetto, A.; Pozzato, G.; Marasca, R.; Efremov, D. G.; Guarini, A.; Del Poeta, G.; Foa, R.; Gaidano, G.; Gattei, V. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. Br. J. Haematol. 2011, 153 (1), 3-14.
29. Binder, M.; Muller, F.; Jackst, A.; Lechenne, B.; Pantic, M.; Bacher, U.; Eulenburg, C. Z.; Veelken, H.; Mertelsmann, R.; Pasqualini, R.; Arap, W.; Trepel, M. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 2011, 117 (9),1891-1900.
30. Herishanu, Y.; Gibellini, F.; Njuguna, N.; Hazan-Halevy, I.; Farooqui, M.; Bern, S.; Keyvanfar, K.; Lee, E.; Wilson, W.; Wiestner, A. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk. Lymphoma 2011, 52 (9), 1758-1769.
31. O'Brien, S. M.; Claxton, D. F.; Crump, M.; Faderl, S.; Kipps, T.; Keating, M. J.; Viallet, J.; Cheson, B. D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009, 113 (2), 299-305.
32. Brem, E. A.; Thudium, K.; Khubchandani, S.; Tsai, P. C.; Olejniczak, S. H.; Bhat, S.; Riaz, W.; Gu, J.; Iqbal, A.; Campagna, R.; Knight, J.; Mavis, C.; Hoskin, P.; Deeb, G.; Gibbs, J. F.; Fetterly, G.; Czuczman, M. S.; Hernandez-Ilizaliturri, F. J. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and-resistant lymphomas. Br. J. Haematol. 2011, 153 (5), 599-611.
33. Tsujimoto, Y.; Finger, L. R.; Yunis, J.; Nowell, P. C.; Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation Science 1984, 226 (4678), 1097-1099
34. Otake, Y.; Soundararajan, S.; Sengupta, T. K.; Kio, E. A.; Smith, J. C.; Pineda-Roman, M.; Stuart, R. K.; Spicer, E. K.; Fernandes, D. J. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood 2007, 109 (7), 3069-3075
35. Klasa, R. J.; Gillum, A. M.; Klem, R. E.; Frankel, S. R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 2002, 12 (3), 193-213
36. O'Brien, S. M.; Cunningham, C. C.; Golenkov, A. K.; Turkina, A. G.; Novick, S. C.; Rai, K. R. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol. 2005, 23 (30), 7697-7702.
37. O'Brien, S.; Moore, J. O.; Boyd, T. E.; Larratt, L. M.; Skotnicki, A.; Koziner, B.; Chanan-Khan, A. A.; Seymour, J. F.; Bociek, R. G.; Pavletic, S.; Rai, K. R. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2007, 25 (9), 1114-1120.
38. O'Brien, S.; Moore, J. O.; Boyd, T. E.; Larratt, L. M.; Skotnicki, A. B.; Koziner, B.; Chanan-Khan, A. A.; Seymour, J. F.; Gribben, J.; Itri, L. M.; Rai, K. R. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J. Clin. Oncol. 2009, 27 (31), 5208-5212.
39. Balakrishnan, K.; Burger, J. A.; Wierda, W. G.; Gandhi, V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cellmediated Mcl-1 induction and drug resistance Blood 2009, 113 (1), 149-153
40. Masood, A.; Chitta, K.; Paulus, A.; Khan, A. N.; Sher, T.; Ersing, N.; Miller, K. C.; Manfredi, D.; Ailawadhi, S.; Borrelo, I.; Lee, K. P.; Chanan-Khan, A. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br. J. Haematol. 2011, [Epub ahead of print].
41. Paoluzzi, L.; Gonen, M.; Gardner, J. R.; Mastrella, J.; Yang, D.; Holmlund, J.; Sorensen, M.; Leopold, L.; Manova, K.; Marcucci, G.; Heaney, M. L.; O'Connor, O. A. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 2008, 111 (11), 5350-5358.
42. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68 (9), 3421-3428.
43. Roberts, A. W.; Seymour, J. F.; Brown, J. R.; Wierda, W. G.; Kipps, T. J.; Khaw, S. L.; Carney, D. A.; He, S. Z.; Huang, D. C.; Xiong, H.; Cui, Y.; Busman, T. A.; McKeegan, E. M.; Krivoshik, A. P.; Enschede, S. H.; Humerickhouse, R. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 2012, 30 (5), 488-496.
44. Pogue, S. L.; Kurosaki, T.; Bolen, J.; Herbst, R. B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase. J. Immunol. 2000, 165 (3), 1300-1306.
45. Gobessi, S.; Laurenti, L.; Longo, P. G.; Carsetti, L.; Berno, V.; Sica, S.; Leone, G.; Efremov, D. G. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009, 23 (4), 686-697.
46. Friedberg, J. W.; Sharman, J.; Sweetenham, J.; Johnston, P. B.; Vose, J. M.; Lacasce, A.; Schaefer-Cutillo, J.; De Vos, S.; Sinha, R.; Leonard, J. P.; Cripe, L. D.; Gregory, S. A.; Sterba, M. P.; Lowe, A. M.; Levy, R.; Shipp, M. A. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115 (13), 2578-2585.
47. Hoellenriegel, J.; Coffey, G. P.; Sinha, U.; Pandey, A.; Sivina, M.; Ferrajoli, A.; Ravandi, F.; Wierda, W. G.; O'Brien, S.; Keating, M. J.; Burger, J. A. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012, [Epub ahead of print].
48. Okkenhaug, K.; Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 2003, 3 (4), 317-330.
49. Herman, S. E.; Gordon, A. L.; Wagner, A. J.; Heerema, N. A.; Zhao, W.; Flynn, J. M.; Jones, J.; Andritsos, L.; Puri, K. D.; Lannutti, B. J.; Giese, N. A.; Zhang, X.; Wei, L.; Byrd, J. C.; Johnson, A. J. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116 (12), 2078-2088.
50. Hoellenriegel, J.; Meadows, S. A.; Sivina, M.; Wierda, W. G.; Kantarjian, H.; Keating, M. J.; Giese, N.; O'Brien, S.; Yu, A.; Miller, L. L.; Lannutti, B. J.; Burger, J. A. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118 (13), 3603-3612.
51. Herman, S. E.; Gordon, A. L.; Hertlein, E.; Ramanunni, A.; Zhang, X.; Jaglowski, S.; Flynn, J.; Jones, J.; Blum, K. A.; Buggy, J. J.; Hamdy, A.; Johnson, A. J.; Byrd, J. C. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117 (23), 6287-6296.
52. de Rooij, M. F.; Kuil, A.; Geest, C. R.; Eldering, E.; Chang, B. Y.; Buggy, J. J.; Pals, S. T.; Spaargaren, M. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokinecontrolled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119 (11), 2590-2594.
53. Ponader, S.; Chen, S. S.; Buggy, J. J.; Balakrishnan, K.; Gandhi, V.; Wierda, W. G.; Keating, M. J.; O'Brien, S.; Chiorazzi, N.; Burger, J. A. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119 (5), 1182-1189.
54. Veldurthy, A.; Patz, M.; Hagist, S.; Pallasch, C. P.; Wendtner, C. M.; Hallek, M.; Krause, G. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008, 112 (4), 1443-1452.
55. Amrein, L.; Hernandez, T. A.; Ferrario, C.; Johnston, J.; Gibson, S. B.; Panasci, L.; Aloyz, R. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro Br. J. Haematol. 2008, 143 (5), 698-706.
56. Amrein, P. C.; Attar, E. C.; Takvorian, T.; Hochberg, E. P.; Ballen, K. K.; Leahy, K. M.; Fisher, D. C.; Lacasce, A. S.; Jacobsen, E. D.; Armand, P.; Hasserjian, R. P.; Werner, L.; Neuberg, D.; Brown, J. R. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res. 2011, 17 (9), 2977-2986.
57. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 2004, 18 (16), 1926-1945.
58. Beevers, C. S.; Li, F.; Liu, L.; Huang, S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int. J. Cancer 2006, 119 (4), 757-764.
59. Yee, K. W.; Zeng, Z.; Konopleva, M.; Verstovsek, S.; Ravandi, F.; Ferrajoli, A.; Thomas, D.; Wierda, W.; Apostolidou, E.; Albitar, M.; O'Brien, S.; Andreeff, M.; Giles, F. J. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2006, 12 (17), 5165-5173.
60. Decker, T.; Sandherr, M.; Goetze, K.; Oelsner, M.; Ringshausen, I.; Peschel, C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann. Hematol. 2009, 88 (3), 221-227.
61. Zent, C. S.; LaPlant, B. R.; Johnston, P. B.; Call, T. G.; Habermann, T. M.; Micallef, I. N.; Witzig, T. E. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010, 116 (9), 2201-2207.
62. Morgan, D. O. The Cell Cycle: Principles of Control. London: New Science Press 2007, 1st ed.
63. Phelps, M. A.; Lin, T. S.; Johnson, A. J.; Hurh, E.; Rozewski, D. M.; Farley, K. L.; Wu, D.; Blum, K. A.; Fischer, B.; Mitchell, S. M.; Moran, M. E.; Brooker-McEldowney, M.; Heerema, N. A.; Jarjoura, D.; Schaaf, L. J.; Byrd, J. C.; Grever, M. R.; Dalton, J. T. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009, 113 (12), 2637-2645.
64. Byrd, J. C.; Lin, T. S.; Dalton, J. T.; Wu, D.; Phelps, M. A.; Fischer, B.; Moran, M.; Blum, K. A.; Rovin, B.; Brooker-McEldowney, M.; Broering, S.; Schaaf, L. J.; Johnson, A. J.; Lucas, D. M.; Heerema, N. A.; Lozanski, G.; Young, D. C.; Suarez, J. R.; Colevas, A. D.; Grever, M. R. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109 (2), 399-404.
65. Byrd, J. C.; Peterson, B. L.; Gabrilove, J.; Odenike, O. M.; Grever, M. R.; Rai, K.; Larson, R. A. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin. Cancer Res. 2005, 11 (11), 4176-4181.
66. Flinn, I. W.; Byrd, J. C.; Bartlett, N.; Kipps, T.; Gribben, J.; Thomas, D.; Larson, R. A.; Rai, K.; Petric, R.; Ramon-Suerez, J.; Gabrilove, J.; Grever, M. R. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk. Res. 2005, 29 (11), 1253-1257
67. Lin, T. S.; Ruppert, A. S.; Johnson, A. J.; Fischer, B.; Heerema, N. A.; Andritsos, L. A.; Blum, K. A.; Flynn, J. M.; Jones, J. A.; Hu, W.; Moran, M. E.; Mitchell, S. M.; Smith, L. L.; Wagner, A. J.; Raymond, C. A.; Schaaf, L. J.; Phelps, M. A.; Villalona-Calero, M. A.; Grever, M. R.; Byrd, J. C. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J. Clin. Oncol. 2009, 27 (35), 6012-6018.
68. Stephens, D. M.; Ruppert, A. S.; Blum, K.; Jones, J.; Flynn, J. M.; Johnson, A. J.; Ji, J.; Phelps, M. A.; Grever, M. R.; Byrd, J. C. Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica 2012, 97 (3), 423-427.
69. Tong, W. G.; Chen, R.; Plunkett, W.; Siegel, D.; Sinha, R.; Harvey, R. D.; Badros, A. Z.; Popplewell, L.; Coutre, S.; Fox, J. A.; Mahadocon, K.; Chen, T.; Kegley, P.; Hoch, U.; Wierda, W. G. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J. Clin. Oncol. 2010, 28 (18), 3015-3022.
70. Conroy, A.; Stockett, D. E.; Walker, D.; Arkin, M. R.; Hoch, U.; Fox, J. A.; Hawtin, R. E. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother. Pharmacol. 2009, 64 (4), 723-732.
71. Sher, T.; Miller, K. C.; Lawrence, D.; Whitworth, A.; Hernandez-Ilizaliturri, F.; Czuczman, M. S.; Miller, A.; Lawrence, W.; Bilgrami, S. A.; Sood, R.; Wood, M. T.; Block, A. W.; Lee, K.; Chanan-Khan, A. A. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk. Lymphoma 2010, 51 (1), 85-88.
72. Moutouh-de Parseval, L. A.; Weiss, L.; DeLap, R. J.; Knight, R. D.; Zeldis, J. B. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J. Clin. Oncol. 2007, 25 (31), 5047.
73. Chanan-Khan, A.; Miller, K. C.; Musial, L.; Lawrence, D.; Padmanabhan, S.; Takeshita, K.; Porter, C. W.; Goodrich, D. W.; Bernstein, Z. P.; Wallace, P.; Spaner, D.; Mohr, A.; Byrne, C.; Hernandez-Ilizaliturri, F.; Chrystal, C.; Starostik, P.; Czuczman, M. S. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J. Clin. Oncol. 2006, 24 (34), 5343-5349.
74. Chanan-Khan, A.; Miller, K. C.; Lawrence, D.; Padmanabhan, S.; Miller, A.; Hernandez-Illatazurri, F.; Czuczman, M. S.; Wallace, P. K.; Zeldis, J. B.; Lee, K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011, 117 (10), 2127-2135.
75. Wendtner, C. M.; Hillmen, P.; Mahadevan, D.; Buhler, A.; Uharek, L.; Coutre, S.; Frankfurt, O.; Bloor, A.; Bosch, F.; Furman, R. R.; Kimby, E.; Gribben, J. G.; Gobbi, M.; Dreisbach, L.; Hurd, D. D.; Sekeres, M. A.; Ferrajoli, A.; Shah, S.; Zhang, J.; Moutouh-de Parseval, L.; Hallek, M.; Heerema, N. A.; Stilgenbauer, S.; Chanan-Khan, A. A. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leuk. Lymphoma 2012, 53 (3), 417-423.
76. Ferrajoli, A.; Lee, B. N.; Schlette, E. J.; O'Brien, S. M.; Gao, H.; Wen, S.; Wierda, W. G.; Estrov, Z.; Faderl, S.; Cohen, E. N.; Li, C.; Reuben, J. M.; Keating, M. J. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111 (11), 5291-5297.
77. Badoux, X. C.; Keating, M. J.; Wen, S.; Lee, B. N.; Sivina, M.; Reuben, J.; Wierda, W. G.; O'Brien, S. M.; Faderl, S.; Kornblau, S. M.; Burger, J. A.; Ferrajoli, A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118 (13), 3489-3498.
78. Lee, B. N.; Gao, H.; Cohen, E. N.; Badoux, X.; Wierda, W. G.; Estrov, Z.; Faderl, S. H.; Keating, M. J.; Ferrajoli, A.; Reuben, J. M. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 2011, 117 (17), 3999-4008.
79. Brown, J. R.; Abramson, J.; Hochberg, E.; Mikler, E.; Dalton, V.; Werner, L.; Reynolds, H.; Thompson, C.; McDonough, S. M.; Kuang, Y.; Ritz, J.; Neuberg, D.; Freedman, A. S. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia 2010, 24 (11), 1972-1975.